Amanta Healthcare initiated its IPO on September 1, attracting significant interest, particularly from retail investors. The IPO was oversubscribed 4.6 times, indicating that more than four times the number of offered shares were requested. Retail investors applied for 6.7 times the available shares, while non-institutional investors also demonstrated solid demand. Conversely, institutional investors exhibited lower interest. The shares are anticipated to list at approximately ₹151, representing a 20% increase from the IPO price. Nevertheless, investors are advised to thoroughly examine the company’s information before making investment decisions. Amanta Healthcare aims to raise ₹126 crore through the sale of 1 crore shares, with a price range set between ₹120 and ₹126 per share.
The minimum purchase requirement is 119 shares, totaling around ₹15,000. Proceeds from the IPO are intended for constructing new factories and acquiring equipment in Gujarat, as well as covering other corporate expenses. Amanta Healthcare specializes in producing specialized liquid medicines using cutting-edge technology. The IPO is being overseen by Beeline Capital Advisors.
